⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

Official Title: Phase II Study of Weekly Paclitaxel/Carboplatin in Combination With Prophylactic G-CSF in the Treatment of Gynaecological Cancers

Study ID: NCT01523678

Study Description

Brief Summary: Rationale: The administration of prophylactic G-CSF may reduce the toxicity of a weekly paclitaxel/carboplatin regimen in gynaecological cancers. Purpose: This multicenter phase II trial is studying the side effects of weekly paclitaxel/carboplatin when given with prophylactic G-SCF in patients with recurrent epithelial ovarian-, primary peritoneal or fallopian tube cancers, endometrial carcinoma or cervical carcinoma. Data obtained in this trial will be compared with historical data as published earlier. The trial will include 3 cohorts of 36 patients: * Subjects with ovarian, fallopian tube or peritoneal carcinoma * Subjects with endometrial cancer * Subjects with cervical carcinoma Treatment: Subjects will receive Paclitaxel 60 mg/m² followed by Carboplatin AUC 2.7 intravenously weekly during 18 weeks. Filgrastim (Neupogen) will be given to all patients on day 5 and possibly on day 6 of each course. Subjects will be evaluated by CT/MRI scan after 9 cycles of chemotherapy (week 10), after 18 cycles of chemotherapy, then every 6 months for the next 2 years and then if clinically indicated. Subjects who develop disease progression will discontinue therapy. Subjects who have no evidence of disease progression after completion of study therapy will be followed until disease progression, withdrawal of informed consent, or death.

Detailed Description: Primary objective: - To evaluate the occurrence of grade 4 neutropenia during weekly paclitaxel/carboplatin with prophylactic G-CSF Secondary objectives: * To evaluate per cohort the occurrence of grade 4 neutropenia * To evaluate other toxicities * To evaluate the dose reductions or dose delays in the chemotherapy * To determine the progression free survival according to RECIST v1.1 * To evaluate the response rate and overall survival

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Cliniques du Sud-Luxembourg, Arlon, , Belgium

Imeldaziekenhuis, Bonheiden, , Belgium

AZ Klina, Brasschaat, , Belgium

Grand Hôpital de Charleroi, Charleroi, , Belgium

St. Maarten Duffel, Duffel, , Belgium

UZ Antwerpen, Edegem, , Belgium

Jan Yperman Ziekenhuis, Ieper, , Belgium

AZ Groeninge, Kortrijk, , Belgium

CHU Tivoli, La Louvière, , Belgium

UZ Leuven, Leuven, , Belgium

Centre Hospitalier de l'Ardenne, Libramont, , Belgium

Centre Hospitalier Régional de la Citadelle, Liège, , Belgium

CHU Sart Tilman Liège, Liège, , Belgium

Cliniques et maternité St. Elizabeth, Namur, , Belgium

AZ Damiaan, Oostende, , Belgium

AZ Nikolaas, Sint-Niklaas, , Belgium

Cliniques universitaires UCL de Mont-Godinne, Yvoir, , Belgium

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: